BIOCHINA and Life Science Nation Team Up to Advance China–Global Biotech Partnerships

Collaboration connects Chinese innovation with international licensing partners at RESI JPM and BIOCHINA 2027

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

BOSTON and SUZHOU, China — Chinese biotech is changing the global partnering landscape. Life Science Nation (LSN) and Enmore BIO, organizer of BIOCHINA, are teaming up in 2027 to connect the companies driving that change with international licensing partners seeking their next opportunity.

The collaboration launches during J.P. Morgan Healthcare Week at RESI JPM, January 11–12 at the San Francisco Marriott Marquis, and continues at BIOCHINA, March 10–12 in Suzhou. Through reciprocal programs and coordinated outreach, the organizations will bring their communities together across two major life science gatherings. At RESI JPM, BIOCHINA will lead a one-hour China-focused session exploring how AI, innovation capabilities, and evolving partnership models are shaping the next generation of Chinese biotech. The discussion will bring Chinese industry leaders into direct conversation with RESI’s global licensing and partnering community about emerging technologies, business opportunities, and international collaboration.

At BIOCHINA, LSN will lead a reciprocal one-hour session on how international partners evaluate emerging companies, assess the team behind the science, and build productive relationships with founders. Final session titles and speakers will be announced separately.

“Both communities are looking across borders for their next opportunity,” said Dennis Ford, Founder and CEO of Life Science Nation. “Chinese companies are developing assets that global pharma is evaluating for future pipelines. International companies are seeking scientific relationships, development capabilities, and partners in China. Our job is to bring the right people together and help those conversations turn into business.”

The collaboration gives both organizations a platform to build a two-way innovation bridge—helping Chinese companies reach international markets while opening connections into China for global companies and strategic partners. Joint promotion through newsletters, industry networks and digital channels will extend the programs’ reach and introduce participants to opportunities across both communities.

The relationship has a proven starting point: LSN and Enmore Healthcare co-organized the first RESI Shanghai on November 12, 2019. Their 2027 collaboration brings those networks together again to advance the next generation of international partnerships.

About Life Science Nation

Life Science Nation connects emerging companies across drugs, devices, diagnostics and digital health with global investors and licensing partners through its databases, education, investability assessments, campaign services and RESI conference series.

About BIOCHINA

Founded in 2016, BIOCHINA has grown into the Asia-Pacific’s leading biotech industry event, with over 33,000 registered attendees by 2026. Centered on evolving industry needs, BIOCHINA integrates Exhibition, Conference, Partnering, and Events to: Connect supply and demand across the value chain, Share the latest technological trends, Drive project collaborations and funding, Promote global biotech cooperation. Moving forward, BIOCHINA remains committed to connect Innovators & enable Bio-industry.

RESI: https://www.resiconference.com/
BIOCHINA: https://www.biocn.cn/

The Business of Biotech Joins Next Phase

By Caitlin Dolegowski, Program Director, LSN

Building a biotech company requires far more than breakthrough science. It demands navigating complex organizational, funding, regulatory, and manufacturing realities. Starting with this issue, Life Science Nation (LSN) is bringing The Business of Biotech podcast directly into Next Phase, giving our community regular, in-inbox access to peer-driven executive insights on advancing novel therapies from early concepts to clinical success.

About The Business of Biotech

Created exclusively for the leaders of new and emerging biotech and pharmaceutical companies, The Business of Biotech tackles funding, R&D and organizational strategy, regulatory policy, manufacturing, and commercial considerations with insight from company founders, investors, and industry experts with lived experience translating novel science into new medicines.

Meet the Host: Ben Comer

The podcast is hosted by Ben Comer, Chief Editor of Life Science Leader magazine and Host of The Business of Biotech. Ben has covered the biopharmaceutical, medtech, and medical device industries for 15 years as a reporter and editor, and previously worked as a senior manager in PwC’s Health Research Institute. His deep industry background brings sharp, operational focus to every founder conversation.

What to Expect in Next Phase

Across Therapeutics, Medical Devices, Diagnostics, and Digital Health, LSN’s mission is to connect early-stage innovators with the global capital and licensing partners that move technologies forward. Embedding The Business of Biotech into Next Phase adds an executive storytelling dimension to our weekly newsletter, allowing readers to learn directly from founders actively building today’s biopharma companies.

Listen to this week’s featured episode below.

On this week’s episode of the Business of Biotech, Paul Peter Tak, M.D., Ph.D., CEO at Candel Therapeutics, talks about the path from Phase 3 data to BLA submission for aglatimagene in localized prostate cancer and why “in situ immunization” could change how solid tumors are treated. He also talks through leadership and operating choices for minimizing risk in late-stage development, how FDA’s Fast Track and RMAT designations aided communication and CMC planning, and how an outsourced commercial model can help companies prepare for launch and avoid premature fixed costs.

Help Shape Group Hotel Rates for Biotech Week Boston & RESI 2027: Take the 30-Second Lodging Survey

By Caitlin Dolegowski, Program Director, LSN

As the life science calendar ramps up, planning is already actively underway for next year’s Biotech Week Boston and the concurrent RESI Boston partnering conference.

Every autumn, thousands of early-stage biopharma and medtech founders, active investors, corporate pharmaceutical business development executives, and service providers descend upon Massachusetts. While the week delivers immense value through high-stakes dealmaking, one persistent hurdle facing attendees year after year is Boston’s notoriously tight lodging market.

To help our community manage travel overhead and secure prime accommodations, the Life Science Nation (LSN) and RESI conference operations team is currently actively negotiating discounted room blocks with premier 4-star properties across the Back Bay and Copley area – right in the central corridor of the week’s key activities.

To ensure we secure the deepest volume discounts and reserve the appropriate room inventory for your team, we need your direct input.

Why Lodging in Boston Requires Advance Coordination

Hotel pricing across central Boston spikes significantly during Biotech Week, driven by global industry demand. Individual reservations made late in the cycle often face exorbitant rack rates or require staying far outside the primary event clusters.

By consolidating the collective purchasing power of our attending founders, investors, and regional tech hub delegations, LSN negotiates dedicated group blocks designed to:

  • Cap Peak-Rate Volatility: Lock in pre-negotiated, below-market room rates during one of the city’s highest-occupancy weeks.
  • Keep Teams Centrally Located: Anchor attendees within walking distance of The Westin Copley Place and key partnering venues, eliminating unnecessary commute friction across town.
  • Guarantee Sufficient Inventory: Provide your executive team, board members, and business development leads with confirmed space before room blocks sell out.

Take the 30-Second Lodging Survey

Our room block allocations and target rate negotiations directly depend on the aggregate requirements of the companies planning to participate.

Whether your organization plans to send a single executive or an entire delegation, please take 30 seconds to share your general lodging preferences:

Take the 30-Second Biotech Week Boston Hotel Survey

(The survey is completely anonymous, requires no login, and takes under a minute to complete.)

What Happens Next

Your feedback on target price points, stay duration, and room count will directly equip our negotiation team as we finalize contracts with Back Bay hotel partners in the coming weeks. Once group blocks are locked in, confirmed booking links and preferential access will be shared with registered delegates and newsletter subscribers.

Thank you for helping us make Biotech Week Boston both highly productive and cost-effective for the early-stage life science community.

For any specific questions regarding group delegations, corporate sponsorships, or partnering registration, please reach out to the RESI team at resi@lifesciencenation.com.

Take the 30-Second Biotech Week Boston Hotel Survey

The Problem Isn’t Access to Capital. It’s Being Investable. Why early-stage life science companies need a commercialization engine, not another introduction

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

For years, LSN ran an investment banking program for early-stage life science companies. It taught us something important: capital-raising solutions work best when a transaction is imminent. For most early-stage companies, it isn’t. Seed, Series A, and Series B companies are still working through the scientific, clinical, regulatory, commercial, and financing risks that determine whether investors will engage. They pitch technology and market potential. Investors ask what’s been proven, which risks have been retired, and what evidence is still missing. More introductions won’t close that gap. These companies need more than deal preparation. They need a commercialization process that can run for months or years.

The Commercialization Engine
LSN is building one with global partners: universities, research institutes, regional clusters, and innovation programs with technology-rich ecosystems. Our partners advance discoveries, generate evidence, and retire development risks. LSN provides assessment intelligence, investability preparation, and access to the global capital and licensing marketplace. LSN’s agentic AI engines support this process. They help evaluate companies through the eyes of investors and licensing partners, an approach already used with more than 250 clients. They also identify and rank relevant global capital and licensing targets.

Stage Commercialization Capability
Scientific assessment and de-risking Scientific and commercialization partners
Investability preparation LSN Investability Assessment, LSN Labs, de-risked decks
Partner identification LSN Matching Engine and Global Target Lists
Campaign execution BD Assist
Global partnering RESI Conference Series

Companies enter wherever their readiness puts them. Agentic AI tools are becoming widely available. LSN’s advantage is the global network, relationships, proprietary databases, and market intelligence built through years of direct work with investors, licensing partners, and companies. That depth of intelligence goes well beyond the cursory matches available from web searches.

BD Assist: Where Preparation Becomes Execution
A seasoned CEO may know a few dozen investors and can find a few hundred more. That still isn’t enough. LSN’s Matching Engine generates a Global Target List of 800–1,000 prospective capital and licensing partners. BD Assist puts that intelligence to work through sustained outreach, engagement tracking, and follow-up over the 9–18 months that early-stage campaigns can require. The CEO leads investor relationships, negotiations, and transactions. LSN manages targeting intelligence, sets up the meetings, and provides campaign support. The cost is $5,000 a month, with no success fee. LSN leverages databases that capture current and forward-looking mandates and historical VC and Pharma transactions, then integrates into all of LSN’s RESI events to add face-to-face or virtual meetings with investors and licensing partners worldwide.

Who Is the Perfect Fit for BD Assist?
The ideal client is an experienced life science CEO who knows how to raise capital and has an investable asset and a credible development plan. What they lack is the global reach and campaign infrastructure to pursue hundreds of prospective investors and licensing partners. This CEO doesn’t need someone to explain fundraising or negotiate a term sheet. They need a dedicated team to identify the right global targets, run a disciplined campaign, and keep opportunities moving while they run their company. BD Assist is not for every company that needs money. Companies still working through fundamental scientific or investability issues may first need assessment, de-risking, and preparation.

The CEO knows how to raise the money. LSN provides the global intelligence and reach, including meeting setup and campaign infrastructure, to help them find it.

To see whether BD Assist is the right fit for your company, contact the LSN team. LSN BD will provide a free investability assessment report, show you what your global target list should look like, and offer commentary on your messaging for your target audience.

Get Your LSN Labs Company Assessment Report

Watch the Asset Flow, Not the Equity Flow: What I Learned at BioJapan

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

I recently returned from BioJapan, and the one takeaway I want to share with my global network is this: stop viewing Asia Pacific as a single market.

Regulations on both sides of the Pacific have made equity deals between the US and China much harder. But capital hasn’t stopped moving. It has changed form. Where equity deals run into friction, pharma licenses the asset instead. Chinese biotechs out-licensed $60 billion of assets in the first quarter of this year alone, up 73% from the same period a year earlier. That includes AstraZeneca’s deal with CSPC worth up to $18.5 billion. Large pharma faces a steep patent cliff before 2030, so its appetite for clinical-stage assets isn’t going away.

So watch the asset flow, not the equity flow. Here is what actually changed for me in Japan. I went in thinking about APAC as one market with local variations. It isn’t. It is three markets with three completely different jobs, and once you see them separately, the whole region stops looking confusing.

Three Markets, Not One

Each market plays a different role. China produces more assets than its domestic capital can absorb. Australia and Southeast Asia have the clinical infrastructure others can use. Japan and Korea stand out because they have both: a growing supply of academic innovation and deep corporate balance sheets looking for it.

Region Sell Side
(Early-Stage Assets)
Buy Side
(VC / PE / Pharma)
Characterization
Mainland China A large volume of high-quality assets, many moving faster than domestic capital can fund them Domestic equity is selective and US venture investment has pulled back, while global pharma licensing runs at record levels “The Asset Reservoir”
Japan, South Korea, & Taiwan A deep, largely untapped pool of academic assets, alongside mature platforms: ADCs and regenerative medicine in Japan, AI-driven discovery and diagnostics in Korea. Taiwan continues to produce world-class assets Active corporate venture arms and well-capitalized conglomerates “The Strategic Capital Track”
Australia & Southeast Asia Excellent trial infrastructure producing fast, high-quality human data Cross-border investors using local efficiency as a launchpad for global programs “The Clinical Fast Track”

Japan: Where Assets Meet Capital

Universities such as the University of Tokyo, Kyoto University, Keio University, Osaka University, Kobe University, and the University of Tsukuba, with RIKEN anchoring the discovery end, are producing a remarkable range of new assets across drugs, devices, diagnostics, and digital health. What’s new is a coordinated government effort to carry those assets to market:

  • AMED runs a 2:1 double match-up program. When a registered VC invests in a Japanese drug discovery startup, AMED can add up to twice that amount in non-dilutive funding, awarded per pipeline rather than per company, so a startup with three approved programs can draw on it three times.
  • MEDISO, under the Ministry of Health, Labor and Welfare, pairs ventures and university spinouts with experts in regulatory affairs, international development, and fundraising.
  • J-Bridge, run by JETRO, connects international innovators with Japanese corporates.

Three state-backed institutions, answering to different ministries, are working on the same bottleneck, and regional clusters are carrying that work into the field. For global investors and partners, that means Japanese assets now arrive better funded and better prepared, and Japanese corporate capital is easier to reach than it has been in years.

One Japanese advantage almost nobody prices correctly: Japan maintains a conditional, time-limited approval pathway for regenerative medicine products that can grant market access on evidence of probable benefit. No other major market offers that. If you have a cell or gene therapy and have never looked at Japan as a first market rather than a third one, you are leaving an option unexercised.

KBIC, the Kobe Biomedical Innovation Cluster, and LSN are working together to strengthen the commercialization pathway for Japanese life science companies through entrepreneur education, company preparation, capital formation, and international business development. At BioJapan in October, LSN presented joint sessions with KBIC, including one alongside MEDISO, on startup readiness and global fundraising.

RESI Asia: Tokyo and Kobe

That is why RESI is coming to Japan. RESI Asia Japan convenes in Tokyo on April 13, 2027, for global partnering. We expect to announce more events around RESI before and after the 13th

The Bottom Line

Regulatory boundaries have changed the rules, but pharma’s appetite for licensing shows the underlying science has never been more valuable. Watch the asset flow, not the equity flow. I look forward to seeing many of you in Tokyo next April.

RESI Asia Japan Registration:

Japan-base Registration (JPY)
Non-Japan-base Registration (USD)

The Missing Piece in Preparing Life Science Companies for Investors

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

One of the most pervasive problems we see across life science entrepreneurial programs is that Entrepreneurs-in-Residence (EIRs) help companies develop executive summaries and pitch decks that emphasize the science and market opportunity. This approach repeats across incubators, accelerators, universities, and entrepreneurial training programs worldwide.

The problem is that the two sides of the table are speaking different languages. The sell side presents science and market potential, while investors and licensing partners evaluate the seven-layer risk stack: market, technical, regulatory, execution, economic, financing, and exit risk. They want to understand which risks have been retired, which remain, and what evidence supports the company’s ability to overcome them.

This is precisely where LSN spends its time preparing companies for global roadshows and RESI partnering events.

We begin with the LSN assessment, which identifies where the company sits within the risk stack, what has been accomplished, and what remains to be de-risked. We then reconstitute the executive summary and pitch deck to speak the language of risk, supported by evidence rather than simply promoting the science and market opportunity.

We also develop a milestone-driven Gantt chart that shows the development milestones already completed and the value created, the one, two, or three critical milestones ahead for the remainder of the current year, and the subsequent development and de-risking milestones planned for years two and three.

The capital ask becomes the financial expression of the de-risking plan. By calculating the cost of the current and future milestones, the company can explain precisely how much capital it needs, what that capital will accomplish, which risks will be retired, and how achieving those milestones is expected to increase the asset’s value.

This is the fundamental distinction between a conventional pitch deck and a de-risked deck. One emphasizes the promise of the science and the size of the market. The other demonstrates a credible, milestone-driven, financed pathway to making that science investable.

That is the missing commercialization discipline LSN brings to the table, and it is what investors and licensing partners are looking for.

Register for RESI JPM 2027

RESI Boston 2026: Your Complete Conference Guide 

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Life Science Nation (LSN) is pleased to release the RESI Boston 2026 Program Guide for the upcoming hybrid conference, taking place September 22–23 in person at the Westin Copley Place in Boston, followed by virtual partnering on September 25 and September 28–29.

Held during Biotech Week Boston, RESI brings together early-stage life science companies, active investors, strategic partners, and industry leaders for targeted fundraising and business development conversations. The event features the Innovator’s Pitch Challenge, investor panels, workshops, company showcases, and RESI Partnering, the conference’s purpose-built platform for scheduling one-on-one meetings.

The Program Guide offers a comprehensive look at the RESI Boston agenda, including sessions focused on the Boston biotech ecosystem, therapeutic innovation, pharma partnering, strategic capital, health systems, chronic disease care, family office investing, and impact investing. Attendees can also explore the participating investor, sponsor, exhibitor, and company lineup, along with networking opportunities throughout the event.

With partnering underway and meeting calendars continuing to fill in the final weeks before the conference, RESI Boston offers innovators a valuable opportunity to connect directly with investors and strategic stakeholders shaping the future of healthcare.

View the program guide and register for RESI Boston today.

Register for RESI Boston